Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05655507 · ClinicalTrials.gov registry record · Phase 1
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT05655507 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 19 participants.
The verdict
NCT05655507, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
Interventions
- DRUG Zuranolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-04-19 |
| Est. Completion | 2024-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05655507
The ClinicalTrials.gov registry entry for NCT05655507 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zuranolone is the first listed.
NCT05655507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05655507 about?
NCT05655507 is a clinical study titled "Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)". The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
What is the current status of trial NCT05655507?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2023-04-19. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT05655507?
The interventions under investigation include: Zuranolone (DRUG).
Who is sponsoring clinical trial NCT05655507?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.